Is calcitriol treatment associated with improved survival in predialysis patients with chronic kidney disease?
Takayuki Hamano
Correspondence Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Box A8, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
Email hamatea@medone.med.osaka-u.ac.jp
Observational studies have demonstrated that therapy with vitamin D analogs for treatment of secondary hyperparathyroidism is associated with improved survival in patients receiving maintenance hemodialysis. This Practice Point commentary discusses an observational study of male predialysis patients with stage 3–5 chronic kidney disease performed by Kovesdy et al., in which incidence rate ratios for all-cause mortality and combined death or dialysis initiation were found to be significantly lower in patients treated with calcitriol than in non-calcitriol-treated patients. These data are compatible with many experimental data on the beneficial effect of vitamin D analogs on the cardiovascular system, renal structure and renal function. Without data from randomized trials, however, it is still unclear whether calcitriol should be administered to all patients with chronic kidney disease, even those without secondary hyperparathyroidism.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
